Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines

Molecular Cancer Therapeutics

Volumn 3, Issue 1, 2004, Pages 11-20

  Barton, Beverly E ^a   Karras, James G ^b   Murphy, Thomas F ^a   Barton, Arnold ^a   Huang, Hosea F S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; JANUS KINASE; LIPOCORTIN 5; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHOTRANSFERASE INHIBITOR; PICEATANNOL; PROPIDIUM IODIDE; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE POTENTIAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BINDING; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HUMANS; JANUS KINASE 2; JANUS KINASE 3; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; STAT3 TRANSCRIPTION FACTOR; STILBENES; TRANS-ACTIVATORS; TRANSFECTION; TYRPHOSTINS;

EID: 4243156987     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Brewer MK. Prostate cancer: where have we been, where we are, where we are going. World J Surg. 2000;24:1200-4.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1999;49:8-31.
3. Milbank AJ, Dreicer R, Klein EA. Hormonal therapy for prostate cancer: primum non nocere. Urology. 2002;60:738-41.
4. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate. 1996;28:251-65.
5. Ihle JN. STATs and MAPKs: obligate or opportunistic partners in signaling. BioEssays. 1996;18:95-8.
6. Grandis JR, Drenning SD, Chakraborty A, Zhou M-Y, Zang Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest. 1998;102:1385-92.
7. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitski A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-15.
8. Buettner R, Mora LB, Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945-54.
9. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107:351-62.
10. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melham MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA. 2000;97:4227-32.
11. Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 2001;61:3276-80.
12. Niu G, Wright KL, Song L, Haura E, Turkson J, Zhang S, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000-8.
13. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth & Differ. 2002;13:355-62.
14. L in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res. 2000;60:6052-60.
15. L underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res. 2001; 61:1699-706.
16. Yoshida T, Hanada T, Tokuhisa T, Kosai K-i, Sata M, Kohara M, et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med. 2002;196:641-53.
17. Yu Q, Geng Y, Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411:1017-21.
18. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002;62:3351-5.
19. Twillie DA, Eisenberger MA, Carducci MA, Hsieh W-S, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995;45:542-9.
20. Borsellino N, Belidegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995;55:4633-9.
21. Okamoto M, Lee C, Oyasu, R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 1997;59:141-6.
22. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB, et al. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate. 2002;52:123-9.
23. Chung TDK, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 1999;38:199-207.
24. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol. 1994;151:1396-9.
25. Barton BE, Murphy TF, Adem P, Watson RA, Irwin RJ, Huang HS. IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer. 2001;1:19.
26. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37:1-11.
27. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 2000;60:2132-5.
28. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate. 2000;42:239-42.
29. Niu G, Heller R, Catlett-Falcone R, Copola D, Jaroszeski M, Dalton W, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999;59: 5059-61.
30. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62:6659-66.
31. Ni Z, Lou W, Leman ES, Gao AC. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000;60:1225-8.
32. Richter F, Huang HFS, Li MT, Danielpour D, Irwin RJ. Differential effects of retinoic acid and testosterone in carcinoma and non-carcinoma rate prostate epithelial cells. Cell proliferation and expression of epidermal growth factor and retinoic acid receptors. Mol Cell Endocrinol. 1999;153:28-38.
33. Karras JG, McKay RA, Lu T, Pych J, Frank DA, Rothstein TL, et al. STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression. Cell Immunol. 2000;202:124-35.
34. Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JAM, Lammers JWJ, et al. STAT3p, a splice variant of transcription factor STAT3, is a dominant-negative regulator of transcription. J Biol Chem. 1996;271:13221-7.
35. Rotman B, Papermaster BW. Membrane proteins of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. Proc Natl Acad Sci USA. 1966;55:139-43.
36. Legrand O, Perrot J-Y, Simonin G, baudard M, Marie J-P. JC-1: A very sensitive fluorescent probe to test pgp activity in acute myeloid leukemia. Blood. 2001;97:502-8.
37. Mathur A, Hong Y, Kemp BK, Barrientos AA, Erusalimsky JD. Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc Res. 2000;46:126-38.
38. Nasu S, Miles L, Kawabe S, Raju U, Newman RA. Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett. 2002;185:145-51.
39. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dorken B, Daniel PT. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-d riven mitochondrial amplification loop. Oncogene. 2003;22:2236-47.
40. Lin Y, Brown L, Hedley DW, Barber DL, Benchimol S. The death-promoting activity of p53 can be inhibited by distinct signaling pathways. Blood. 2002;100:3990-4000.
41. Seidel HM, Lamb P, Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene. 2000;19:2645-56.
42. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitski A, Kraker A, et al. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem. 2000;275:24935-44.
43. Su L, David M. Distinct mechanisms of STAT phosphorylation via the interferon-α/β receptor. J Biol Chem. 2001; 275:12661-6.
44. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res. 2003;9: 316-26.
45. Campbell CL, Jiang Z, Savarese DMF, Savarese TM. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol. 2001;158:25-32.
46. Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem. 1999;274:21155-61.
47. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295-303.
48. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19:2468-73.
49. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2001;7: 3920-7.
50. Benimetskaya L, Miller P, Benimetsky S, Maciaszek, Guga P, Beaucage SL, et al. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase c-α (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol Pharmacol. 2001;60: 1296-307.
51. Gleave ME, Miyake H, ZellwegerT, Chi K, July L, Nelson C, et al. Use of antisense oligonucleotides targeting the anti-apoptotic gene, clusterin/testosterone-repressed message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology. 2001;58(2 Suppl 1):39-49.
52. Sun X, Layton JE, Elefanty A, Liescke, GJ. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and ST1571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and ST1571. Blood. 2001;97:2008-15.
53. Junicho A, Matsuda T, Yamamoto T, kishi H, Korkmaz K, Saatcioglu F, et al. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun. 2000;278:9-13.
54. Matsuda T, Junicho A, Yamamoto T, Kishi H, Kormaz K, Saatcioglu F, et al. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun. 2001;283:179-87.